Core Insights - Novo Nordisk's stock rose over 2% to $57.12 following positive results from a late-stage clinical trial of its new weight loss drug Cagrilintide [1] Group 1: Clinical Trial Results - Cagrilintide demonstrated significant weight loss in a Phase 3 trial, with patients losing an average of 11.8% of their body weight over 68 weeks, compared to only 2.3% in the placebo group [1] - The drug is a long-acting insulin analog that increases satiety by mimicking hormones secreted alongside insulin in the pancreas, differentiating it from existing GLP-1 medications [1] Group 2: Company Statements - Martin Holst Lange, Chief Scientific Officer and Executive Vice President of R&D at Novo Nordisk, expressed excitement over the trial data, highlighting the drug's distinct mechanism compared to approved obesity medications and its good tolerability [1] - The company looks forward to further validating Cagrilintide's potential in the dedicated Phase 3 RENEW project [1]

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 最新统计数据显示，中国超重和肥胖人群已突破总人口的49%大关。虽然我国肥胖率并非全球最高，但庞大的人口基数使得中国已然成 为世界肥胖人口第一大国。这一严峻形势迫切需要科学界揭示肥胖发生的深层机制。 作为细胞能量工厂的线粒体，其功能异常已被证实与肥胖、胰岛素抵抗及脂肪肝等代谢疾病密切相关。加州大学圣地亚哥分校Al a n R. Sa lti e l教授团队在Na t u r e Me t a bolism发表突破性研究成果，首次阐明高脂饮食会引发白色脂肪细胞内线粒体结构崩解，导致其代谢功 能严重受损。这种线粒体碎片化现象直接阻碍能量消耗，促使脂肪异常蓄积，最终形成恶性循环的肥胖病理过程。 研究团队进一步锁定Ra lA基因为这一过程的关键调控因子。通过基因编辑技术特异性敲除Ra lA基因后，即使持续给予高脂肪饮食，实 验对象仍能维持线粒体完整结构，有效避免体重异常增加。这一发现不仅揭示了肥胖发生的新机制，更为开发靶向Ra lA的减肥疗法提 供了理 ...